Jeffrey Carstens, MD
Cardiovascular Disease · Omaha, NENPI 1730265976
Payments from drug & device makers
Across 558 payments — averaging $536.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$157K
- Edwards Lifesciences$29K
- Lilly USA, LLC$27K
- Amarin Pharma, Inc.$23K
- Medtronic$21K
- Boehringer Ingelheim$19K
- plus $22K from 25 others
What the payments were for
- Consulting fees$38,26531%
- Speaking & faculty fees$33,57027%
- Travel & lodging$29,01323%
- Food & beverage$23,25019%
- Education$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 24 | $157,194 |
| Edwards Lifesciences | 119 | $29,122 |
| Lilly USA, LLC | 23 | $27,455 |
| Amarin Pharma, Inc. | 5 | $23,252 |
| Medtronic(2 entities) | 121 | $20,624 |
| Boehringer Ingelheim | 33 | $19,192 |
| Philips North America LLC | 13 | $9,654 |
| Boston Scientific | 53 | $5,463 |
| Abbott | 26 | $2,183 |
| Novartis | 31 | $755 |
| AstraZeneca | 12 | $571 |
| Siemens Medical Solutions USA, Inc. | 10 | $571 |
| Johnson & Johnson | 13 | $424 |
| Shockwave Medical, Inc | 4 | $385 |
| Saranas, Inc. | 3 | $359 |
| Pfizer | 10 | $359 |
| Impulse Dynamics (USA) Inc. | 4 | $241 |
| E.r. Squibb & Sons, L.L.C. | 6 | $236 |
| Biotronik Inc. | 2 | $231 |
| Amgen | 12 | $193 |
| Sanofi-aventis U.S. LLC | 6 | $189 |
| Penumbra, Inc. | 1 | $150 |
| Teleflex LLC | 2 | $147 |
| Merck | 11 | $138 |
| Chiesi USA, Inc. | 4 | $64 |
| Cardiovascular Systems Inc. | 2 | $52 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $49 |
| Janssen Scientific Affairs, LLC | 1 | $33 |
| Irhythm Technologies, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$46,046
- FFRct$5,081
- Resolute$4,604
- GENERAL - THERAPIES$3,013
- Ingenia 1 5T R5$2,324
- US Und$2,000
- IXR Commodity$2,000
- (7882) Image Guided Therapy Und$1,500
- Micra$1,192
- (7881) Ultrasound Und$808
- IGT Systems Und$521
- Watchman$476
- FARXIGA$375
- SAPIEN 3 Ultra RESILIA$365
- Mitra Clip system$318
- PulseSelect$318
- ENTRESTO$315
- RESOLUTE ONYX$306
- AMPLATZER AMULET$282
- SYMPLICITY G3$277
How this compares
$299,336 in reported general payments places this provider in the 95th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $28,010 |
| XareltoRivaroxaban | 15 | $12,406 |
| JardianceEmpagliflozin | 14 | $9,083 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $392 |
| Metoprolol Succinate | 37 | $363 |
| Atorvastatin Calcium | 41 | $258 |
| Amlodipine Besylate | 32 | $247 |
| Rosuvastatin Calcium | 14 | $175 |
| Carvedilol | 18 | $111 |
| Nitroglycerin | 13 | $109 |
| ClopidogrelClopidogrel Bisulfate | 11 | $86 |
| Spironolactone | 20 | $75 |
| Metoprolol Tartrate | 11 | $66 |
| Furosemide | 43 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $359 | $28,01026 claims |
| Johnson & JohnsonXarelto | $424 | $12,40615 claims |
| Boehringer IngelheimJardiance | $19,192 | $9,08314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Omaha
- Ronald ZoltyOmaha$6.3M
- Joseph ThibodeauOmaha$251K
- Edward OlearyOmaha$104K
- Michael PetersOmaha$90K
- John HenryOmaha$82K
- Amjad KabachOmaha$75K
- Thomas PorterOmaha$64K
- Stanislaw SojkaOmaha$60K
- Qais RadaidehOmaha$50K
- Mark HolmbergOmaha$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.